Portfolio Analysis in Cork.

A patent portfolio analysis Cork manufacturers can act on starts where Munster’s economy does — with the molecule, the process and the device made on the Cork pharma coast. The harbour belt around Ringaskiddy, Carrigtwohill and Little Island is one of Europe’s densest biopharmaceutical clusters: Pfizer runs its largest production site outside the United States here, Janssen (Johnson & Johnson), Novartis, BioMarin and MSD operate advanced manufacturing plants, Eli Lilly is established near Kinsale, and Stryker anchors a major medtech base. For a manufacturer the questions asked of a patent estate differ from a software house’s: how long does patent term plus an SPC really protect this API, where is freedom to operate for a contract job, and which families are worth the renewal fees?

The work is landscape, gap, strength, term and valuation analysis — not litigation. It is the freedom-to-operate map behind a new process route, the supplementary-protection-certificate timeline that decides when a product loses exclusivity, the diligence behind a life-science acquisition, and the pruning decision that stops a large estate overspending at the IPOI and the EPO. PerspireIP builds those studies for the pharmaceutical, API, medtech and deep-tech portfolio owners across Cork and the wider Munster region.

Why patent portfolio analysis Cork owners frame around the molecule and the site

In a software or telecom hub a portfolio review often begins with a standards estate or a financing round. On the Cork pharma coast it begins with the molecule and the manufacturing site. This is one of Europe’s largest concentrations of biopharmaceutical and API production — Pfizer’s Ringaskiddy complex is its biggest site outside the United States, Janssen operates two advanced plants in the harbour, and Novartis, BioMarin, MSD at Brinny and Eli Lilly near Kinsale sit alongside them, with more than 14,000 people employed across Cork’s pharma and medical-device sector. A patent portfolio analysis Cork owners can use has to read an estate the way a plant’s process, regulatory and legal teams do: as the exclusivity clock on a product and the freedom to run a process, not as an abstract count of granted claims.

That framing changes the deliverable. For a manufacturer a patent is rarely a licensing machine — it is the wall around a product’s market and the thing that has to survive a generic or biosimilar challenge on the day term expires. So the study has to grade the strength of the composition, formulation and process claims that actually protect the product, map freedom to operate across rival API and device assignees, and build the true expiry date for every family once patent term, supplementary protection and any paediatric extension are stacked. We build analysis a site director, an IP counsel or a corporate-development team can act on, tied to the launch, deal or budget cycle that prompted it.

• Product and process clearance — freedom-to-operate landscaping before a new route, formulation or device ships from a Cork site
• Exclusivity timelines — the real loss-of-exclusivity date once patent term, an SPC and any paediatric extension are combined
• M&A and asset diligence — validity, ownership chain and product coverage of a target molecule or device before a deal
• Board and budget reviews — a periodic strength, gap and renewal-cost picture for the CTO and general counsel

SPCs, paediatric extensions and patent-term strategy for a Cork site

For a Cork pharmaceutical estate the single most valuable question is often not whether a patent is strong but when protection actually ends. A supplementary protection certificate (SPC) extends the protection of a patent beyond its twenty-year term for up to five years, compensating for the time lost to regulatory approval, and in Ireland SPCs are granted by the Intellectual Property Office of Ireland (IPOI) under the European Communities (Supplementary Protection Certificate) Regulations 2008. On top of that, a six-month paediatric extension is available where the product has completed an agreed paediatric investigation plan, and the IPOI accepts an e-filed request for that extension against an existing SPC.

Stacking those layers correctly is where a review earns its fee. The basic patent, the SPC and the paediatric extension each run on their own rules and their own dates, and the difference between getting the calculation right and wrong can be years of exclusivity on a product manufactured in Ringaskiddy or Brinny. We build the true loss-of-exclusivity date for every product family, check that the right basic patent underpins each SPC, confirm the marketing-authorisation dates that drive the term, and flag where a paediatric extension is available but not yet secured. That timeline is the backbone of any launch, lifecycle-management or divestment decision.

A patent portfolio analysis Cork lifecycle teams can rely on treats term as a strategic asset, not an afterthought. When exclusivity is about to fall, the estate needs a defensive plan — secondary formulation and process patents, new indications, or a considered decision to let a legacy family lapse rather than pay to defend a product already open to generics. We map each product against its term cliff, identify the follow-on filings that genuinely extend protection versus those that only add cost, and give lifecycle and finance teams a clear, dated picture of when revenue is exposed.

Freedom to operate for contract and process manufacturing

Cork is not only a home for originator products — it is a contract and process manufacturing powerhouse, and that reshapes the freedom-to-operate question. When a Cork plant takes on a new API route, a formulation, a fill-finish job or a device sub-assembly for a client, the risk is that the process, the polymorph, an intermediate or an excipient combination reads on a third party’s live patent, even where the client owns the product. A freedom-to-operate study reads that risk before capital is committed and before a batch is made, not after a cease-and-desist arrives.

Solid-state and process chemistry make Cork FTO distinctive. The region built its research reputation partly on crystallisation and solid-state science — the Science Foundation Ireland pharmaceutical research base and University College Cork feed a deep local expertise in polymorphs, salts and co-crystals, exactly the subject matter where a single unexpected patent can block a route. We landscape the patents and published applications that read on a target process, map the polymorph and formulation space around the molecule, and separate the genuine blocking art from the noise, so a plant knows whether a job is clear, needs a design-around, or needs a licence.

• Process and route FTO — clearing the synthesis, intermediates and catalysts against live third-party patents before scale-up
• Solid-state and formulation FTO — polymorph, salt, co-crystal and excipient landscaping around the target molecule
• Device and sub-assembly FTO — clearing medtech components and combination-product features for contract work
• Design-around and licence options — where the art blocks, the practical routes past it and their cost

Grading API, formulation and Cork medtech patent families

Where a Cork estate holds real, ownable value is in the specific inventions: the composition-of-matter and formulation claims on a drug, the process and solid-state patents that protect a route, and the device and combination-product families the region’s medtech base generates. Stryker anchors a substantial orthopaedic and medical-device operation in Cork, biologics work runs at Janssen and MSD, and a wave of contract developers and start-ups files around delivery systems and diagnostics. These are patent-dense fields where strength rests on the wording of particular claims, not on standards declarations or raw family counts.

Grading these families is a discipline in its own right. For a pharmaceutical family the questions are whether the composition claim genuinely covers the marketed product, whether a formulation or process patent would survive a validity attack from a generic entrant, and whether it truly delays entry or merely decorates the annual report. For a medtech family the questions are whether the claims cover the shipping device and its roadmap and whether they block a competitor’s next model. We map each family to a product and a rival, score claim strength and validity risk, and flag the white space where a filing programme should push next.

A patent portfolio analysis Cork research and legal leaders can rely on separates the families that genuinely protect a product from the long tail that only costs renewal fees. For a life-science or device estate that distinction is worth real money: the crown-jewel composition or platform family that underwrites a product gets defended and extended, while legacy families that no longer cover anything on the market become pruning candidates before the next annuity falls due. Counting patents tells you nothing useful; grading each against products, competitors and validity risk tells you everything you need to raise, sell or defend a budget.

Ireland outside the UPC: national validation and enforcement

Here is the fact that reshapes any Irish portfolio strategy. Ireland signed the Agreement on a Unified Patent Court but has not ratified it, because ratification would transfer patent jurisdiction from the Irish courts to an international court and therefore requires a constitutional referendum — the proposed insertion into Article 29 of the Constitution. That referendum was scheduled for June 2024, postponed, and at the time of writing has no confirmed date. The practical consequences are concrete: the unitary patent does not cover Ireland, there is no Irish division of the Unified Patent Court, and the UPC Court of Appeal has confirmed Ireland sits outside its jurisdiction.

So European patent protection in Ireland is obtained and enforced nationally. A granted European patent takes effect in Ireland without the translation cost that burdens many other states, because Ireland is a London Agreement country and English is an official language shared with the EPO — no translation of the specification is required to bring an EP into force here. That keeps Irish coverage comparatively cheap and makes Ireland an efficient market to hold, but it also means every enforcement action, every revocation defence and every opt-out decision plays out on the national stage rather than in the pan-European court.

A patent portfolio analysis Cork owners commission has to price that posture deliberately. Because Ireland is outside the unitary system, a family that matters here needs a validated national leg regardless of any unitary election made elsewhere in Europe, and enforcement strategy has to be built around the Irish High Court rather than a Regional Division. We grade each family for its Irish coverage, flag where a unitary election has inadvertently left an Irish gap, and read the referendum uncertainty as a genuine planning variable — because if Ireland eventually ratifies, the enforcement map for these estates changes, and a portfolio plan should anticipate both outcomes.

The Commercial Court fast track and where Cork disputes are decided

When an Irish patent dispute does arise, it is decided nationally, and the venue matters to how a portfolio is graded. Patent infringement and revocation actions are heard in the High Court in Dublin, where either party can apply to transfer the case into the Commercial List — the Commercial Court — under Order 63A of the Rules of the Superior Courts, with proceedings brought under the Patents Act 1992 among the qualifying criteria. The Commercial Court is a case-managed fast track, and once a matter is admitted a trial date can follow far more quickly than the years a general High Court action once took.

That fast track shapes strategy for a Cork estate on both sides of a dispute. For a manufacturer defending a product it means a validity or non-infringement position has to be ready earlier, because active case management compresses the timetable. For a portfolio owner seeking to enforce, it means a strong, well-documented family can move to trial on a commercially useful schedule rather than languishing. We grade families with that timetable in mind — identifying the crown-jewel patents robust enough to carry a Commercial Court action and the vulnerable ones better kept out of a fight — and we read where an Irish action would sit relative to any parallel European proceedings.

The IPOI sits alongside the courts in that picture. It grants Irish national patents and also offers a short-term patent, valid for up to ten years, for which evidence of novelty is not required at grant — a route that can suit a fast-moving device or process innovation from a Cork start-up. A portfolio review reads which assets are full-term national or European rights and which are short-term patents, because the two carry very different strength, term and enforcement profiles, and a buyer, licensee or opponent will scrutinise the difference closely.

How PerspireIP builds a patent portfolio analysis Cork owners can act on

Every engagement follows the same disciplined path, scaled to whether you are clearing a process, defending an exclusivity cliff, prepping a data room or planning next year’s filings. We inventory the portfolio, verify legal status and ownership, map each asset to products and competitors, grade strength, term and Irish coverage, and price the estate for the decision that prompted the review.

• Full inventory with legal-status, patent term, SPC and paediatric-extension timeline for every product family across the IPOI and EPO routes
• Product-to-patent coverage mapping and a claim-strength score across the estate
• Freedom-to-operate landscaping for new process routes, formulations and devices against the major pharma, API and medtech assignees
• Loss-of-exclusivity modelling stacking patent term, SPCs and paediatric extensions for each product
• Irish national coverage and outside-UPC enforcement grading, with a Commercial Court readiness view for the crown-jewel families
• Renewal-fee pruning recommendations plus a valuation view for financing, M&A or licensing, delivered as data-room-ready exhibits

We work alongside your in-house IP team, corporate-development group or outside counsel as a specialist analysis partner, deliver to your launch or budget calendar, and keep every engagement confidential. Whether you need a one-time diligence study before a Cork acquisition, a freedom-to-operate read for a new contract-manufacturing job, or an annual portfolio health check for the board, we scale to fit. Send us the assignee name or a patent list and we will scope a patent portfolio analysis Cork project within one business day.

IP Landscape & Resources in Cork

Key intellectual-property authorities and venues relevant to Cork:

• Intellectual Property Office of Ireland (IPOI) — grants Irish national and short-term patents, administers supplementary protection certificates and paediatric extensions, and maintains records of European patents in force in Ireland
• European Patent Office (EPO) — grants the European patents that, because Ireland is outside the unitary system, must be held nationally to protect a product in Ireland
• Courts Service of Ireland — administers the High Court and its Commercial List, the case-managed fast track where Irish patent infringement and revocation actions are decided
• Tyndall National Institute (University College Cork) — Cork's deep-tech and ICT research institute at University College Cork, anchoring much of the region's semiconductor, photonics and medtech innovation

Request a Patent Portfolio Analysis in Cork

Explore related PerspireIP services: Patent Portfolio Analysis services · IP services in Ireland · patent invalidation · prior art and litigation search · patent infringement analysis · patent monetization.

Frequently Asked Questions